Welcome to our dedicated page for ISEE news (Ticker: ISEE), a resource for investors and traders seeking the latest updates and insights on ISEE stock.
Iveric Bio, Inc. (NASDAQ: ISEE) is a prominent biopharmaceutical company dedicated to the development of innovative therapeutics targeted at diseases affecting the back of the eye. The company's primary focus is on age-related macular degeneration (AMD), a significant cause of vision loss among older adults. Iveric Bio is at the forefront of ophthalmology research, advancing drugs that could potentially transform the treatment landscape for retinal diseases.
One of the company's notable projects is the development of Avacincaptad Pegol, aimed at treating Geographic Atrophy secondary to AMD, a condition that leads to irreversible blindness. This drug is currently in advanced stages of clinical trials, poised to make a substantial impact upon receiving regulatory approval.
In a significant development, on July 11, 2023, Iveric Bio was acquired by Astellas Pharma Inc. (TSE: 4503). This acquisition, valued at approximately $5.9 billion, marks a strategic expansion for Astellas into the ophthalmology sector. The merger combines Iveric Bio's extensive expertise and promising drug pipeline with Astellas' robust global presence and resources, setting the stage for accelerated progress in developing and commercializing treatments for retinal diseases.
Following the acquisition, Iveric Bio's common stock was delisted from NASDAQ. The successful completion of this acquisition signifies a new chapter for Iveric Bio, with enhanced capabilities to bring groundbreaking ophthalmic therapies to market.
Iveric Bio remains committed to its mission of addressing unmet medical needs in eye care through pioneering research and development. As a subsidiary of Astellas, it is well-positioned to leverage combined strengths, promising a future where advancements in treatment for retinal diseases can significantly improve patient outcomes globally.
For more detailed and up-to-date information, investors and stakeholders are encouraged to follow the latest news releases and updates from both Iveric Bio and Astellas Pharma.
Iveric Bio (NASDAQ: ISEE) has granted equity-based awards to eight new non-executive employees under its 2019 Inducement Stock Incentive Plan, as approved by its compensation committee. The inducement grants include stock options for 200,000 shares and 43,000 restricted stock units. The stock options have an exercise price of $10.33, the same as the closing price on June 1, 2022, and will vest over four years. The Company is focused on developing treatments for retinal diseases, aiming to meet significant unmet medical needs.
IVERIC bio (NASDAQ: ISEE) announced that President Pravin U. Dugel, M.D., will participate in a fireside chat at the UBS Global Healthcare Conference on May 23, 2022, at 10:45 a.m. Eastern Time. The event will be accessible via a live webcast on the Investor Events section of IVERIC's website, with an archived replay available for 30 days post-conference. IVERIC bio focuses on developing innovative treatments for retinal diseases, aiming to improve patient outcomes in conditions like age-related macular degeneration.
Iveric Bio (NASDAQ: ISEE) announced that President Pravin U. Dugel, M.D. will present a corporate overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting May 24 at 7:00 a.m. ET, and an archived replay will be accessible for 30 days afterward. Iveric Bio specializes in developing treatments for retinal diseases, aiming to improve patient outcomes for conditions like age-related macular degeneration.
IVERIC bio announced significant updates in its Q1 2022 results, highlighting the GATHER2 clinical trial nearing completion with a 94% milestone achieved. The company anticipates reporting topline data in Q3 2022, aiming for an NDA submission for Zimura®, a complement inhibitor for geographic atrophy (GA). The injection fidelity rate exceeded expectations, targeting over 90%. Financially, Q1 net loss was $34.5 million, with R&D expenses rising to $22.6 million. The company holds approximately $345.7 million in cash, sufficient to fund operations into mid-2024.
Iveric Bio announced a post-hoc analysis of the GATHER1 clinical trial results for Zimura (avacincaptad pegol), assessing its impact on geographic atrophy (GA) lesion growth. The findings will be presented at the Retinal World Congress on May 13, 2022, in Fort Lauderdale, FL. The analysis shows consistent reduction in GA lesion growth in patients receiving Zimura compared to sham across all baseline distances from the foveal center. Zimura met its primary efficacy endpoint in GATHER1, and topline results from the ongoing GATHER2 trial are anticipated in Q3 2022, with potential FDA and EMA submissions following positive results.
Iveric Bio (NASDAQ: ISEE) announced on May 2, 2022, that it granted equity-based awards to six newly-hired, non-executive employees under its 2019 Inducement Stock Incentive Plan. These grants, approved by the compensation and talent strategy committee, included 156,000 non-statutory stock options and 13,500 restricted stock units, aimed at attracting talent. The stock options have an exercise price of $14.29 and a ten-year term, with a vesting schedule of four years. Iveric Bio focuses on developing treatments for retinal diseases.
Iveric Bio (NASDAQ: ISEE) is set to release its first quarter 2022 financial and operational results on May 4, 2022. The company's management will hold a live conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. Iveric Bio focuses on developing innovative treatments for retinal diseases. Interested participants can join the call by dialing in or accessing the live webcast through the company's investor relations website.
Iveric Bio, a biopharmaceutical company focused on retinal diseases, announced that Pravin U. Dugel, M.D., its President, will participate in a fireside chat at B. Riley Securities' Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 9:00 a.m. ET. The event will be accessible via live webcast on the Iveric Bio website, with an archived replay available for 30 days following the conference. Iveric Bio aims to develop innovative treatments for retinal diseases, including age-related macular degeneration.
Iveric Bio (NASDAQ: ISEE) announced on
Iveric Bio (NASDAQ: ISEE) announced on
FAQ
What is the market cap of ISEE (ISEE)?
What is Iveric Bio's primary area of focus?
What significant recent event involved Iveric Bio?
What is Avacincaptad Pegol?
What happened to Iveric Bio's stock following the acquisition by Astellas?
How will the acquisition by Astellas benefit Iveric Bio?
Who was the CEO of Iveric Bio prior to the acquisition?
What is the significance of Geographic Atrophy in AMD?
What are the future prospects for Iveric Bio under Astellas?
Who is the President of Iveric Bio?
Where can I find more information about Iveric Bio and Astellas?
